From: Mannose-binding lectin does not explain the course and outcome of pregnancy in rheumatoid arthritis
Cohort | Patients (n= 214) | Controls (n= 31) |
---|---|---|
MBL genotype group A, n (%) | 114 (53.3) | 16 (51.6) |
MBL genotype group B, n (%) | 59 (27.6) | 8 (25.8) |
MBL genotype group C, n (%) | 41 (19.2) | 7 (22.6) |
Number of Caucasians, n (%) | 207 (96.7) | 31 (100) |
Number of nulliparous women, n (%) | 113/214 (52.8) | 14/31 (45.2) |
Mean age at delivery, yr (± SD) (range) | 32.5 ± 3.7 (21.9 to 40.6) | 32.1 ± 4.5 (24.2 to 40.1) |
Mean gestational age at delivery, wk (range) | 39.4 (31.4 to 42.1) | 40.0 (34.7 to 42.0) |
Smoking during pregnancy, n (%) | 6/206 (2.9) | 3/31 (9.7) |
Miscarriage, n (%) | 23 (10.7) | - |
Hypertension, n (%) | 25/210 (11.7%) | 2 (6.5) |
Preeclampsia, n (%) | 4/210 (1.9) | 1 (3.2) |
Anti-CCP-positive, n (%) | 134/213 (62.9) | - |
Rheumatoid factor (IgM)-positive, n (%) | 161/214 (75.1) | - |
Erosive disease, n (%) | 136/210 (64.8) | |
Median disease duration at delivery, yr (range) | 7.9 (0.7 to 29.0) | - |
Use of prednisone in first trimester, n (%) | 60/164 (36.6%) | |
Median number of DMARDs (including prednisone) prior to conceive (min-max) | 2.3 (0-6) | - |
Use of methotrexate prior to conception, n (%) | 120/212 (56.6) | - |
DAS28-CRP3 >3.2 in first trimester, n (%) | 84/155 (54.2) | - |
Classification of disease activity during pregnancy | ||
Good response or moderate response, n (%) | 40/84 (47.6) | - |
No response, n (%) | 44/84 (52.4) | - |
Classification of disease activity during postpartum period (early flare) | ||
Severe or moderate deterioration, n (%) | 39/167b (23.4) | - |
No deterioration, n (%) | 128/167b (76.6) | - |
Classification of disease activity during postpartum period (late flare) | ||
Severe or moderate deterioration, n (%) | 28/152b (10.3) | - |
No deterioration, n (%) | 124/152b (45.6) | - |